‘Zombie squirrels' sightings have been reported in Maine and Canada
These growths are consistent with squirrel fibromatosis, a common and typically non-lethal skin disease caused by a virus.
The virus spreads through direct contact between squirrels or via biting insects, though the growths usually regress on their own within weeks or months.
Wildlife experts confirm that squirrel fibromatosis is not transmissible to humans, domestic pets, or birds, advising residents to leave affected animals alone.
The reports follow earlier sightings of 'Frankenstein bunnies' in Colorado, which are rabbits affected by shope papillomavirus, another condition not harmful to humans or pets.
'Frankenstein rabbits' scare prompts new fears of 'zombie squirrel' plague
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
27 minutes ago
- Reuters
Viking's weight-loss pill data disappoints, shares sink
Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a mid-stage trial, missing Wall Street's top-end expectations of 15% and sending its shares plummeting by 41%. In the 280-person study of obese and overweight adults, those who received the highest 120-milligram dose of Viking's drug, VK2735, shed 12.2% of their body weight on average over 13 weeks versus 10.9% for those who received a placebo. However, about 20% of patients on VK2735 dropped out of the study due to adverse effects, primarily gastrointestinal issues such as vomiting and nausea, compared to 13% in the placebo group. The company will consider increasing it every four weeks for future studies, rather than every two weeks, to help control the side effects, Viking CEO Brian Lian said. Oral weight-loss drugs are expected to widen access for patients averse to injections, helping their makers tap into a projected $150 billion market currently dominated by Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound. But so far, oral pills have failed to outperform the injectables in the tight race for these medicines. Analysts expected Viking's drug to help lower body weight by 10% to 15%, following an 8.2% average reduction in an early-stage trial. J.P. Morgan analyst Hardik Parikh said the drug's profile did not measure up to earlier trials, but said side effects might be manageable with dose adjustments, particularly given the high discontinuation rate in the placebo group. Shares of Viking had gained 4.6% this year till Monday's close due to optimism over the obesity pill. In early August, Lilly's experimental daily pill, orforglipron, showed a 12.4% weight loss in a late-stage study over 72 weeks. The news wiped off more than $100 billion from the company's market value on the day. Separately, Novo's oral semaglutide has shown a weight-loss of 15% over 68 weeks. Both drugmakers expect to launch their oral drugs by next year.
Reuters
27 minutes ago
- Reuters
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder
Aug 19 (Reuters) - The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' (PTCT.O), opens new tab oral medication for a rare genetic disorder with limited treatment options, the company said on Tuesday. In its so-called Complete Response Letter, the FDA said the data did not provide substantial efficacy evidence for the drug, vatiquinone, in treating Friedreich's ataxia and that a separate study was needed before resubmitting the application. At least three analysts said the regulator's rejection was not surprising and that expectations had been low heading into the decision. PTC's shares reversed premarket losses to rise more than 8% in morning trading. The FDA approved Sephience - PTC's oral therapy for a rare metabolic disorder called phenylketonuria - last month, potentially countering revenue declines due to regulatory scrutiny and competition from cheaper rivals for its top-selling muscular disorder therapies, Translarna and Emflaza. "We see today's CRL as a clearing event since investors can now turn their focus to the Sephience launch," analysts said in a client note. The company said it planned to meet with FDA officials to discuss potential next steps. "We are of course disappointed by the FDA's decision to not approve vatiquinone," CEO Matthew Klein said, adding that the data till date demonstrated that the drug could be safe and effective for children and adults living with the disorder. Friedreich's ataxia is a rare genetic disorder that causes progressive damage to the nervous system, often leading to difficulty in walking, speech problems and heart complications. The disease tends to develop in children and teenagers and gradually worsens over time. Vatiquinonedid not meet its main goal, opens new tab of significantly reducing disease progression in a key late-stage trial that was part of the company's marketing application. Currently, Biogen's (BIIB.O), opens new tab Skyclarys remains the only FDA-approved treatment for Friedreich's ataxia.
The Independent
an hour ago
- The Independent
Half-off Ozempic? US patients paying in cash can now buy the popular weight-loss drug for less
American diabetes patients will now be able to buy the wildly popular weight-loss drug Ozempic for half its usual price — as long as they pay out of pocket. Danish pharmaceutical company Novo Nordisk said on Monday that it would make the drug available through its direct pharmacy service for $499 per month, compared to a list price of just under $1,000 per month. The drug is available as an obesity medication under the alternate brand name Wegovy but will now be sold to patients with diabetes prescriptions as well. Scientifically known as semaglutide, Ozempic and other GLP-1 agonists have rapidly transformed weight loss and diabetes treatment across the world, while at one point boosting Novo Nordisk's profits enough to raise the entire GDP of Denmark. It comes after President Donald Trump specifically called out GLP-1 agonists for being more expensive in the U.S. than in other countries, claiming he would "slash the cost of prescription drugs" by as much as 80 percent. He also accused European nations of "unfairly shifting the cost burden onto American patients" by using the bargaining power of their large single-payer healthcare services to force U.S. pharma companies to accept lower prices. Big Pharma has been responsive, with Pfizer CEO Albert Bourla recently admitting that he and other firms are discussing ways to make their drugs available more cheaply. Sales of Ozempic surged by 500 to 600 percent in the U.K. after its competitor Mounjaro announced that prices would more than triple starting on September 1. But Trump's tariffs could also raise the price of U.S. drugs that are manufactured abroad unless pharma companies or foreign governments can agree some exemption. Novo Nordisk launched its NovaCare pharmacy in March, offering Wegovy for $499 to patients willing to skip insurance and forego any reimbursement. More recently the president upgraded his promise on drug prices to say he would cut them by up to "1,500 percent", which is mathematically impossible without going into negative numbers. In Ozempic's case, reducing the list price by 1,500 percent would result in Novo Nordisk paying American patients around $14,000 for a month's supply of the drug — which is unlikely.
